8-Prenylnaringenin (8-PN · Most Potent Dietary Phytoestrogen · Hops)

Compound	8-Prenylnaringenin (8-PN; 5,7,4′-Trihydroxy-8-prenylflavanone; (S)-8-Prenylnaringenin)
Chemical class	Polyphenol — Prenylated Flavanone (naringenin with C5 dimethylallyl group at C-8; highest ERalpha affinity of any dietary compound)
CAS	53846-50-7
Primary source	Humulus lupulus (hops female cones — produced from xanthohumol/isoxanthohumol by CYP1A2 O-demethylation)
Key applications	Phytoestrogenic (most potent dietary); menopausal hot flush; bone density; cardiovascular; skin ageing
Claim strength	Moderate
Typical form	Hops Flower Extract Powder (8-PN co-delivered with xanthohumol and isoxanthohumol); standardised 8-PN hops extract
Buy from Herbuno	Hops Flower Extract Powder - Humulus lupulus →

Name origin: 8-Prenylnaringenin is named by its structural position — naringenin (the flavanone base) with a prenyl (dimethylallyl, C5) group at carbon-8 of the A-ring. The "-8-" positional prefix is critical: bavachin is 6-prenylnaringenin (C-6 prenylation), while 8-PN carries the prenyl at C-8, giving fundamentally different 3D geometry and receptor binding properties. Traditional use: 8-Prenylnaringenin has no direct traditional medicinal use — it is present in hops at low concentrations (0.05–0.1% of hops dry weight) and was not identified as a significant constituent until analytical chemistry revealed it in the 1990s. The historical use of hops for sedation, sleep, and female reproductive complaints (hop pickers in 19th century England were observed to have altered menstrual cycle timing) aligns with 8-PN's phytoestrogenic activity, providing retrospective pharmacological explanation. Research trajectory: 8-PN is the most potent known dietary phytoestrogen — with ERα binding affinity 0.5–4% that of oestradiol, substantially higher than genistein (~4% ERβ, ~0.1% ERα) and equol (~0.2% ERα). This ERα affinity is pharmacologically significant for menopausal applications — ERα mediates most of the vasomotor and bone effects of oestrogen. Multiple European RCTs with 8-PN-standardised hops extract have been conducted for menopausal hot flush reduction. Commercial source: 8-Prenylnaringenin is available from Herbuno via Hops Flower Extract Powder, which delivers 8-PN alongside xanthohumol and isoxanthohumol as the characteristic hops prenylated flavonoid spectrum.

---

Evidence for 8-PN Applications

Menopausal hot flush reduction (RCT evidence): Multiple European double-blind RCTs have evaluated 8-PN-standardised hops extract for menopausal symptoms. Heyerick et al. 2006 (Maturitas) demonstrated significant hot flush reduction with 8-PN-enriched hops extract versus placebo. The ERα mechanism — directly relevant to hypothalamic thermoregulatory neuron modulation — provides the strongest mechanistic rationale for 8-PN's vasomotor symptom activity among all plant phytoestrogens. Claim strength: Moderate.

Bone density: 8-PN activates ERα in osteoblast models more potently than any other dietary phytoestrogen, stimulating bone formation markers (RUNX2, alkaline phosphatase, osteocalcin) and inhibiting osteoclastogenesis via ERα-RANKL/OPG modulation. In ovariectomised rodent models, 8-PN preserves bone mineral density comparably to low-dose oestrogen treatment. Human bone density RCT data specifically for 8-PN are limited; the ERα mechanism supports bone density positioning based on pharmacological first principles. Claim strength: Moderate (animal/mechanistic).

Cardiovascular: ERα-mediated eNOS activation, vasodilation, and LDL oxidation reduction at concentrations relevant to 8-PN supplementation. Anti-atherosclerotic effects in ApoE-knockout mouse models have been documented. Claim strength: Emerging.

Skin ageing: ERα-mediated skin collagen synthesis stimulation and hyaluronic acid production in dermal fibroblasts — similar to the mechanism by which oestrogen maintains skin thickness and elasticity in premenopausal women. Topical 8-PN preparations for post-menopausal skin ageing are an emerging application area. Claim strength: Emerging.

---

Dosage & Formulator Specification

European menopausal RCTs have used hops preparations standardised to deliver approximately 100–200 μg/day 8-PN (0.1–0.2 mg/day) — extraordinarily low doses relative to other phytoestrogen supplements (genistein 54 mg/day, equol 20 mg/day). This reflects 8-PN's substantially higher ERα affinity — nanomolar tissue concentrations are sufficient for measurable receptor activity. Higher doses (0.5–1 mg/day 8-PN) have been used in other studies without significant adverse effects.

Hops Flower Extract from Herbuno delivers 8-PN as a minor constituent of the total hops polyphenol spectrum. For precision dosing at the RCT-effective range (100–200 μg/day), standardised 8-PN-enriched hops extract (≥0.1% 8-PN by HPLC) from specialty hops extract manufacturers (providing 0.1–0.2 mg per 100–200 mg serving) is appropriate. The 8-PN concentration in standard hops flower extract is typically 0.05–0.1% — borderline for delivering RCT-effective doses in standard serving sizes.

8-PN's stability is better than xanthohumol — the saturated C2-C3 bond of the flavanone ring is more resistant to thermal cyclisation than xanthohumol's chalcone system. However, the prenyl group undergoes oxidative degradation — nitrogen packaging and antioxidant co-formulation (vitamin E, rosemary extract) protect 8-PN integrity. Aqueous solubility is poor (logP ~3.5); microencapsulation or cyclodextrin complexation for beverage/powder applications is recommended.

Safety considerations: 8-PN's ERα activity is the highest of any dietary compound — the same cautions applied to pharmaceutical oestrogens apply, though at substantially lower potency. Contraindications in ER-positive breast cancer, endometrial cancer, and pregnancy apply. Unlike equol's ERβ selectivity, 8-PN's ERα activity means it stimulates both ER-positive tissue growth and protective ERβ-mediated effects — the safety profile for hormone-sensitive cancers requires professional oversight. At the 0.1–0.2 mg/day doses studied in RCTs, systemic ERα activity is expected to be modest and unlikely to significantly increase breast cancer risk, but long-term data are not available.

---

Frequently Asked Questions — 8-Prenylnaringenin

Why is 8-PN considered the most potent dietary phytoestrogen?
Among all dietary compounds tested in ER binding assays, 8-PN has the highest ERα binding affinity — approximately 0.5–4% that of oestradiol. For comparison: genistein ~0.1% ERα; equol ~0.2% ERα; coumestrol ~20% ERα (higher than 8-PN for ERα, making this a contested ranking). Using ERβ, equol and coumestrol rank higher than 8-PN. The "most potent" designation is typically applied to 8-PN based on ERα affinity + bioavailability considerations — 8-PN is absorbed more reliably than coumestrol at dietary plant concentrations, making its effective phytoestrogenic potency in vivo arguably highest among common dietary phytoestrogens.

How is 8-PN produced from xanthohumol in the body?
Two metabolic steps: (1) Thermal cyclisation (during beer brewing) or intestinal bacterial cyclisation of xanthohumol's open-chain chalcone to isoxanthohumol (a flavanone with a methoxy group at C-4′); (2) CYP1A2-mediated O-demethylation of isoxanthohumol's 4′-methoxy group to reveal the 4′-hydroxyl of 8-PN. This two-step pathway means hops-consuming individuals (whether via beer or supplement) produce 8-PN from xanthohumol/isoxanthohumol precursors, with 8-PN production dependent on gut microbiome and hepatic CYP1A2 activity.

What dose of 8-PN is effective for menopausal hot flushes?
RCT evidence suggests 100–200 μg/day (0.1–0.2 mg/day) 8-PN from standardised hops extract is sufficient for modest but significant hot flush frequency reduction. This is 100–200× lower than typical genistein doses for comparable effects — reflecting 8-PN's ERα potency advantage. Dose-response optimisation has not been comprehensively established in human trials; the 0.1–0.5 mg/day range appears to be the clinically relevant window based on available data.

Should 8-PN or equol be preferred for menopausal applications?
These have distinct mechanistic profiles: 8-PN is ERα-preferring (higher ERα:ERβ affinity ratio); equol is ERβ-selective. For vasomotor symptoms (hot flushes), ERα activity is the primary mechanism — 8-PN's ERα activity gives a stronger theoretical basis for hot flush reduction. For bone density and cardiovascular protection, ERβ activity is more relevant — equol's ERβ selectivity is advantageous and carries a cleaner safety profile for long-term use. Combination of low-dose 8-PN (vasomotor ERα) with equol (bone/cardiovascular ERβ) may provide the broadest menopausal benefit spectrum — a formulation strategy supported by mechanistic rationale, though direct clinical testing of this combination is lacking.

Related compounds: Xanthohumol, Equol, Bavachin, Genistein

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery